Bristol Droxia Approved For Sickle Cell Anemia With Carcinogenicity warning
Executive Summary
Bristol-Myers Squibb will assess Droxia for carcinogenicity in additional animal studies and in a long-term Phase IV study that follows patients enrolled in the pivotal trial.